Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

NCT07663747 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Bladder Cancer

Interventions

DRUG: Enfortumab Vedotin
DRUG: Pembrolizumab
RADIATION: Radiation
OTHER: Chemoradiation
PROCEDURE: Cystectomy

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]
[object Object]